UNSPSC 51261600: Adrenergic blocking agent amines

This classification denotes adrenergic blocking agents made from a group of compounds derived from ammonia by substituting organic radicals for the hydrogens.

UNSPSC 51261600 Adrenergic blocking agent amines is a Class code that captures state and local procurement of naloxone and related emergency pharmaceutical interventions, though recent activity under this code shows a mismatch between the nominal category name and actual buying patterns. Seminole County, Florida is procuring naloxone units and drug deactivation systems through competitive bidding to support community health and opioid-response initiatives, with annual volumes of 1,900 units of naloxone and 800 deactivation systems delivered quarterly. The Texas Health and Human Services Commission posted a Request for Information to gather vendor capabilities on direct-to-manufacturer prescription fulfillment models that could reshape how state health agencies source pharmaceuticals outside traditional pharmacy benefit manager and group purchasing organization channels. Issuing bodies soliciting under this code include county health departments and state health and human services agencies; the activity reflects growing state and local focus on opioid-response infrastructure and prescription-program efficiency.

Recent activity is concentrated in Florida and Texas. Seminole County issued IFB 60459723LAS on June 30, 2026, with a bid response deadline of July 26, 2023, seeking naloxone and drug deactivation systems with quarterly delivery to the Seminole County Community Health Building in Sanford; the contract carries a two-year initial term with an option for one-year renewal and includes probationary termination rights and FEMA compliance requirements. The Texas HHS Commission posted RFI HHS0017013 on April 3, 2026, with the same-day response deadline, to explore vendor experience with direct manufacturer contracting for prescription fulfillment outside traditional PBM and GPO arrangements, signaling potential future formal procurement once the state completes market research. Both opportunities reflect state and local agencies moving beyond conventional pharmaceutical supply chains to address specific health priorities — opioid response in the county context and prescription-cost management at the state level.